IL293776B1 - Methods for treating parkinson's disease - Google Patents

Methods for treating parkinson's disease

Info

Publication number
IL293776B1
IL293776B1 IL293776A IL29377622A IL293776B1 IL 293776 B1 IL293776 B1 IL 293776B1 IL 293776 A IL293776 A IL 293776A IL 29377622 A IL29377622 A IL 29377622A IL 293776 B1 IL293776 B1 IL 293776B1
Authority
IL
Israel
Prior art keywords
disease
methods
treating parkinson
parkinson
treating
Prior art date
Application number
IL293776A
Other languages
English (en)
Hebrew (he)
Other versions
IL293776A (en
Original Assignee
Meiragtx Uk Ii Ltd
Meiragtx Neuro I Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meiragtx Uk Ii Ltd, Meiragtx Neuro I Llc filed Critical Meiragtx Uk Ii Ltd
Publication of IL293776A publication Critical patent/IL293776A/en
Publication of IL293776B1 publication Critical patent/IL293776B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/51—Lyases (4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y401/00—Carbon-carbon lyases (4.1)
    • C12Y401/01—Carboxy-lyases (4.1.1)
    • C12Y401/01015—Glutamate decarboxylase (4.1.1.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Psychology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL293776A 2019-12-12 2020-12-14 Methods for treating parkinson's disease IL293776B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962947418P 2019-12-12 2019-12-12
PCT/US2020/064928 WO2021119615A1 (en) 2019-12-12 2020-12-14 Methods for treating parkinson's disease

Publications (2)

Publication Number Publication Date
IL293776A IL293776A (en) 2022-08-01
IL293776B1 true IL293776B1 (en) 2026-07-01

Family

ID=76330812

Family Applications (1)

Application Number Title Priority Date Filing Date
IL293776A IL293776B1 (en) 2019-12-12 2020-12-14 Methods for treating parkinson's disease

Country Status (10)

Country Link
US (1) US20230050187A1 (cg-RX-API-DMAC7.html)
EP (1) EP4072568A4 (cg-RX-API-DMAC7.html)
JP (2) JP7758671B2 (cg-RX-API-DMAC7.html)
KR (1) KR20220114028A (cg-RX-API-DMAC7.html)
AU (1) AU2020403266A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022011584A2 (cg-RX-API-DMAC7.html)
CA (1) CA3161322A1 (cg-RX-API-DMAC7.html)
IL (1) IL293776B1 (cg-RX-API-DMAC7.html)
MX (1) MX2022007193A (cg-RX-API-DMAC7.html)
WO (1) WO2021119615A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026085129A1 (en) * 2024-10-15 2026-04-23 MeiraGTx Neuro I, LLC High-dose gad gene therapy for treating parkinson's disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001089583A2 (en) * 2000-05-23 2001-11-29 Neurologix, Inc. Glutamic acid decarboxylase (gad)_delivery system for treating neurodegenerative diseases
US20050025746A1 (en) * 2000-05-23 2005-02-03 Neurologix, Inc. Glutamic acid decarboxylase (GAD) based delivery systems
WO2018232055A1 (en) * 2017-06-15 2018-12-20 Voyager Therapeutics, Inc. Aadc polynucleotides for the treatment of parkinson's disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030087264A1 (en) * 2001-05-22 2003-05-08 Kaplitt Michael G. Transcriptional regulation of target genes
EP1893754A4 (en) * 2005-05-31 2009-01-21 Neurologix Inc NEW GLUTAMIC ACID DECARBOXYLASE (GAD) CHIMESES AND USE PROCESSES

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001089583A2 (en) * 2000-05-23 2001-11-29 Neurologix, Inc. Glutamic acid decarboxylase (gad)_delivery system for treating neurodegenerative diseases
US20050025746A1 (en) * 2000-05-23 2005-02-03 Neurologix, Inc. Glutamic acid decarboxylase (GAD) based delivery systems
WO2018232055A1 (en) * 2017-06-15 2018-12-20 Voyager Therapeutics, Inc. Aadc polynucleotides for the treatment of parkinson's disease

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ALLEN PATRICIA J ET AL:, GENE-BASED THERAPIES IN PARKINSON'S DIS, 16 October 2013 (2013-10-16) *
KAPLITT ET AL.:, SAFETY AND TOLERABILITY OF GENE THERAPY WITH AN ADENO-ASSOCIATED VIRUS (AAV) BORNE GAD GENE FOR PARKINSON'S DISEASE: AN OPEN LABEL, PHASE I TRIAL, 21 June 2007 (2007-06-21) *
LUO JIA ET AL:, SUBTHALAMIC GAD GENE THERAPY IN A PARKINSON'S DISEASE RAT MODEL, 11 October 2002 (2002-10-11) *
NIETHAMMER MARTIN ET AL:, LONG-TERM FOLLOW-UP OF A RANDOMIZED AAV2-GAD GENE THERAPY TRIAL FOR PARKINSON'S DISEASE, 6 April 2017 (2017-04-06) *

Also Published As

Publication number Publication date
KR20220114028A (ko) 2022-08-17
US20230050187A1 (en) 2023-02-16
EP4072568A1 (en) 2022-10-19
EP4072568A4 (en) 2024-02-07
JP7758671B2 (ja) 2025-10-22
MX2022007193A (es) 2022-09-19
BR112022011584A2 (pt) 2022-12-13
JP2023506007A (ja) 2023-02-14
WO2021119615A1 (en) 2021-06-17
AU2020403266A1 (en) 2022-08-04
CA3161322A1 (en) 2021-06-17
JP2025188191A (ja) 2025-12-25
IL293776A (en) 2022-08-01